Mitochondrial DNA (mtDNA) diseases are inherited maternally by both male and female offspring, since all mitochondria are derived from the oocyte cytoplasm. Most symptoms result in severe disability as the muscles, heart and other vital organs, which require high cellular energy production, are heavily affected. Currently, treatments for such syndromes are limited and supportive, aiming to hinder progression of the disease, rather than restorative. The most severely affected patients die very young having lived a very poor quality of life. Alternative therapies are needed, including those which are preventative. However, with developments in mitochondrial transfer techniques many ethical issues have been raised regarding such treatments, which involve transfer of nuclear material into donated oocytes with healthy mitochondria, or the introduction of healthy donor mitochondria into affected oocytes. Blastomere, ooplasmic, pronuclear and spindle transfer have been explored. Ethical concerns relate to (a) the alteration of germ line genetics and (b) the dilemma of children inheriting DNA material from three instead of two parents. In contrast to gene therapy, where only the DNA of the treated individual is altered, these techniques involve the introduction of foreign mtDNA into the germ line that will be inherited by all children in downstream generations. Mitochondrial transfer has also been closely associated with reproductive cloning, which is regulated differently worldwide. Children born from these techniques might experience an identity crisis. Although three gametes are needed to produce a healthy embryo in this scenario, the child will inherit all nuclear DNA from the intending parents, while only inheriting mtDNA from the donor. Social and scientific values must be considered when introducing new healthcare technology. Many believe that some assisted reproductive technology techniques go beyond the limits of acceptable medical intervention. But who ultimately decides what is acceptable? We address the ethical and social issues surrounding this emerging new technology, legal developments regarding its clinical introduction in the UK and the USA, the future impact on technique and patient management, and relevant legislation in South Africa.
resulting child will be the first of its kind and not a clone of an already existing human. However, many from the professional health and public sectors reject this technology. Internationally, there are differing bioethical and legal regulations concerning human cloning (for reproductive, therapeutic and research purposes). A report in 2006 summarised these regulatory approaches from 16 countries. Cloning concerns are especially applicable to the blastomere nuclear transfer technique, where a blastomere is derived from an embryo that consists of several cells, not just a single cell as found during transfer of spindles or pronuclei (Fig. 1). Potentially, several blastomeres could be transferred to several enucleated oocytes and give rise to genetically identical offspring. The blastomeres of a single embryo could be used on different occasions resulting in ‘delayed’ twins. This could be avoided by using one embryo per recipient oocyte, or one embryo per cycle. Alternatively, a multiple embryo transfer can be performed if multiple blastomeres of a single embryo are used for multiple recipient oocytes. Additionally, a completely new cycle could be initiated for each potential pregnancy. The approach would be unique to each patient, depending on how many embryos are available and how many resultant embryos survive and implant.

Is ‘three-parent IVF’ a sensationalised term?

The second ethical issue is the dilemma of children inheriting DNA material from three instead of two parents. The prevention of mtDNA disease transmission has been dubbed ‘three-parent IVF’. The general public have been led to believe that this will cause psychosocial problems for children born from these techniques, as they might experience an identity crisis. Three gametes are needed to produce a healthy embryo in this scenario. However, a crucial point is that the child will inherit all nuclear DNA from the intending parents, while only inheriting the mtDNA from the donor. Mitochondrial DNA possesses less than 30 genes, while nuclear DNA encodes approximately 25,000 genes. Furthermore, mtDNA is highly conserved among humans (Professor Douglas C. Wallace, University of Pennsylvania, personal communication), and to an extent across species, as mitochondrial energy production is a universal function required by all living organisms. By scale of quantity (number of genes) and quality (gene function), it is misleading for a resultant child to be led to believe that its physical attributes are derived from three, not two, sets of parental DNA.

On the other hand, it can be questioned whether some phenotypic characteristics are highly accounted for by the mtDNA – physical strength or sports ability, for instance. Unfortunately, such an argument is not applicable in a clinical setting where a couple is unable to have a healthy child that can live to adulthood. Their primary concern is not whether their child will inherit the best mitochondria possible to become an olympic athlete. Furthermore, it has not been proven whether physical strength can be attributed to specific variants of mtDNA genes, mtDNA mutations with an evolutionary advantage, or number of mtDNA copies. Perhaps, physical ability is only partially or completely unrelated to the sequence or natural reserve of mtDNA. Nuclear genes and physical practice could be more responsible for this phenotype.

Other kinship forms that challenge the argument of loss of identity in children with ‘three’ parents include adoption, surrogacy and use of donor gametes (sperm or oocytes alike) or gestational carriers. Such children could experience the same psychosocial issues. While not possessing DNA from three parents, they have the potential to experience a crisis in terms of how they fit into their families, as in

Fig. 1. Spindle(a) and pronuclear(b) transfer techniques.

ICSI = intracytoplasmic sperm injection. mtDNA = mitochondrial DNA. nDNA = nuclear DNA. IVF = in vitro fertilisation.
theory they have more than two biological and social parents. Applying this sensationalism on a broader scale, would children born through embryo donation then have four parents? Nevertheless, researchers have suggested that if a paternal female relative is available and willing to donate oocytes for the mitochondrial transfer treatment, offspring will inherit paternal mtDNA and all nuclear DNA of the intending parents. Thereby the child will theoretically not possess any foreign DNA from a third party. Additionally, excluding adoption, all cases have a genetic aspect involved. Use of donor gametes and surrogate mothers, of course, result in a complete difference of genetic material between the child and one of the intending parents, causing them to be biologically unrelated. With regard to the use of surrogacy or a gestational carrier, the development of the fetus does not take place in the intending mother’s uterus. This alteration of the developmental environment causes epigenetic alterations in the fetal DNA. In this way, the woman that carries the child makes an indirect genetic contribution to the child since epigenetic alterations in the fetal DNA. In this way, the woman that carries the child makes an indirect genetic contribution to the child since epigenetic DNA changes do modify the child’s phenotype and can even cause disease.

On the grounds that adoption, fostering, step-parenting, surrogacy, and gamete donation are widely accepted in society today, the use of mitochondrial donors is only an extension of current forms of kinship. It seems unlikely that individuals born by these novel procedures would experience more or any psychosocial issues. Researchers conducting evaluations of donor conceived children consider that persons born through mitochondrial transfer techniques would better fit into the category of naturally conceived children, than donor conceived children, when it comes to their psychological wellbeing. The mitochondrial donor should not necessarily be regarded as a second mother or parent to the resulting child, as this is refutable on both biological and legal principles (‘Mater semper certa est’). There is also evidence that individuals usually cope quite well with information regarding their origins (be they genetic, biological and/or social) provided that they are told at a relatively young age (during their pre- or primary school years) and in a controlled manner. It is probably advisable for children born by preventative mtDNA disease techniques to be informed at an early age, and that this is reported to them with sufficient information about the procedures and relatively small genetic contribution from the donor.

**Future management**

The Nuffield Council on Bioethics of the United Kingdom (UK) has reviewed the novel micromanipulation techniques, which can be utilised for the prevention of mtDNA disorders. The report concluded no overall ethical objection to the use of these technologies in humans for treatment of mtDNA disease, although further investigation is needed to confirm the safety of the techniques. They also recommend that patients are provided with appropriate information and support before and throughout the treatment. Suitable trained and updated individuals should deliver information to prospective patients.

To broaden our knowledge and monitor the outcome of these therapies, the Nuffield Council also advises follow-up and assessment of the resulting children. In terms of regulation, other recommendations also stipulate that the status of mitochondrial donors should differ from oocyte or embryo donors and their identity need not necessarily be disclosed to the children once they reach adulthood. This could potentially be a positive feature of this type of donation and result in more women being willing to donate their oocytes for these treatments, as the legalities of gamete donation can discourage some persons from donating. In 2014 the UK government proposed change in legislation to grant mitochondrial donors anonymity.

The Food and Drug Administration (FDA) of the USA, in February 2014, discussed drafting guidelines for the design of clinical trials, but has not published the final document. It was acknowledged that clinical research would also be needed for validation of mitochondrial replacement to treat female infertility. The committee agreed on inclusion criteria for participants and the use of ‘historical controls’. Manufacturing controls and quality assessment of techniques, and how these factors could contribute to risk reduction for the participants and their future children, were also discussed. The FDA Cellular, Tissue and Gene Therapies Advisory Committee concluded that currently there is a lack of animal data to commence human clinical trials. Some members suggested additional research in alternative animal species concurrently as no single model emulates human physiology. Aspects to be considered in these studies to supplement current data include:

- Sufficient subject numbers
- Evaluation from embryonic to postnatal stages
- Follow-up (including analysis of neurologic, cardiopulmonary and motor function)
- Assessment of the redox state
- Mitochondrial carryover
- Adverse nuclear-mitochondria interaction.

Other concerns raised included risks to the fetus and resulting children, many of which mirrored those in the UK report. Additionally, the committee reviewed the ethics of participation of these future children in clinical trials without informed consent. The FDA recommends setting up ‘centres of excellence’ in order to achieve standardisation of mitochondrial manipulation methods.

Undoubtedly, mitochondrial replacement therapy has a worthy place in assisted reproduction in the near future, as its benefit outweighs the associated ethical issues. Safety and efficacy must be optimised before human use but there is hope for families that want to prevent transmission of a mitochondrial disorder to their offspring. When developing a new medical therapy one needs to consider first and foremost alleviation of suffering to the patients and their families.

**Genetic manipulation in South Africa**

The South African National Health Act 61 of 2003 (NHA), Chapter 8: ‘Control of use of Blood, Blood Products, Tissue and Gametes in Humans’ states:

‘A person may not –
(a) manipulate any genetic material, including genetic material of human gametes, zygotes or embryo; or
(b) engage in any activity, including nuclear transfer or embryo splitting, for the purpose of the reproductive cloning of a human being.’

The document further defines ‘reproductive cloning of a human being’ as: ‘the manipulation of genetic material in order to achieve the reproduction of a human being and includes nuclear transfer or embryo splitting for such purpose.’

The NHA does not mention alteration of germ line genetics or reproductive embryo cloning. Transfer of mtDNA even in the form of blastomere nuclei (the technique which has been scrutinised the
most by ethicists) is not ‘reproductive cloning of a human being’. The document also does not specify that genetic material may not be manipulated for any other reasons. Does this mean that one could undertake mitochondrial transfer in the realms of the South African legal context? It is likely that ministerial authorisation will be required.

Concluding remarks and perspectives

Both the social and scientific aspects of a new healthcare technology must be considered. Regarding social and moral principles, many believe that some ART techniques go beyond the border of acceptable medical intervention. It is reasonable that these opinions should be considered, but who decides on what is globally acceptable and what is not? Diverse social, ethical, religious, cultural, political, scientific and clinical bodies will have differing attitudes. Public opinion can also make a difference today, more than it could in the past. However, is the public aware of techniques that have been in place for decades in assisted reproduction technology, without appropriate evidence-based data being gathered before implementation? The introduction of novel germ line therapies into humans has proved how important it is for the gap between scientific fact and public opinion to be overcome. The Nuffield Council on Bioethics has achieved this through a comprehensive review of the issues surrounding prevention of mtDNA disease by examining the techniques from many angles. The report also highlighted how some features of the therapies do not truly deviate from what is already considered socially acceptable.

However, once mitochondrial transfer becomes available to patients, long-term follow-up monitoring of the resultant children born by these techniques must be performed.

The UK Department of Health has published draft regulations for new techniques to prevent the transmission of mitochondrial disease. These regulations suggest creation of a national or worldwide database that can easily be accessed to encourage information sharing of patient data and improvement and optimisation of the techniques. The UK parliament has debated mitochondrial transfer since 2012 and in February 2015 finally voted in favour of human mitochondrial replacement legislation to allow the commencement of human clinical application. These Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 will apply from 29 October 2015.

With regard to South African legislation, alteration of germ line genetics and cloning other than reproducing human beings is not mentioned, and it is not clear whether the lack of information on these techniques implies that they are not prohibited.

Funding. This research and the publication thereof is the result of funding provided by the Medical Research Council of South Africa in terms of the MRC's Flagships Awards Project SAMRC-RFA-UFS-P-01-2013/ STEM CELLS.

References